Several cities across China, including Shanghai, Nanjing, Suzhou, Fuzhou, and Chengdu, have recently begun offering the human papillomavirus (VPH) vaccine to male residents. This development marks a significant step in expanding HPV prevention efforts beyond the female population.
While HPV is often associated with cervical cancer in women, medical experts stress that vaccinating males plays a crucial role in reducing transmission and preventing HPV-related diseases in men.
The quadrivalent HPV vaccine, developed by the pharmaceutical company Merck, was officially approved for use in males on the Chinese mainland on January 8. This vaccine provides protection against HPV types 6, 11, 16, et 18. It is available to individuals aged 9 pour 26 for males and 9 pour 45 for females. The full vaccination schedule consists of three doses, with each shot priced at approximately 800 yuan ($109).
Why HPV Vaccination for Males Matters
While high-risk HPV strains are widely recognized as the leading cause of cervical cancer in women, the impact of HPV on men is often overlooked. According to Dr. Sui Long, chief physician at the cervical disease diagnosis and treatment center of the Obstetrics and Gynecology Hospital of Fudan University, certain HPV strains also contribute to significant health risks in males.
“HPV types 6 et 11 account for nearly 90 percent of genital warts, while HPV types 16 et 18 are linked to about 90 percent of anal cancers,” Docteur. Sui explained. En outre, since routine HPV screenings for men are not widely available, infections and related diseases are often detected at more advanced stages.
Recent studies suggest that the HPV infection rate among men in China may be higher than that of women. Data from a U.S.-based study estimated that men with at least one heterosexual partner have a lifetime HPV infection probability of 91.3 pour cent, compared to 84.6 percent in women.
Optimal Vaccination Timing for Males
Huang Zhuoying, deputy director of the Institute of Immunization at the Shanghai Municipal Center for Disease Control and Prevention, emphasized the importance of vaccinating males before they reach peak infection rates. “The highest risk of initial HPV infection in males occurs between 18 et 24 ans,” Docteur. Huang stated. “Receiving the vaccine before this age window offers the best protection.”
Beyond genital infections, HPV can also affect the mouth, gorge, and skin, leading to tumors and other serious conditions. Chez les hommes, the virus spreads primarily through sexual contact and direct skin or mucosal contact.
Public Health Impact of Gender-Inclusive Vaccination
Experts believe that broadening HPV vaccination coverage to include both males and females will have far-reaching public health benefits. “Including males in vaccination programs will substantially lower HPV transmission rates, reduce the financial burden of screenings and treatments, and accelerate progress toward eliminating cervical cancer,” Docteur. Huang added.
Eligible males can schedule vaccination appointments at designated community health centers and hospitals.
China’s Commitment to HPV Prevention
In line with global health initiatives, the World Health Organization (OMS) launched a strategy in 2020 to eliminate cervical cancer. The plan aims for 90 percent of girls to be vaccinated by age 15, 70 percent of women to be screened by ages 35 et 45, et 90 percent of women diagnosed with cervical disease to receive timely treatment by 2030.
China introduced its own action plan in 2023, setting similar goals to enhance HPV prevention and control nationwide.
By extending HPV vaccination to males, China is taking a crucial step toward reducing overall infection rates and safeguarding public health for future generations.
